Get the Stockscreener App
8.265
4.38%
-0.405
Immunitybio Inc stock is traded at $8.265, with a volume of 14.91M.
It is down -4.38% in the last 24 hours and up +19.62% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.67
Open:
$8.29
24h Volume:
14.91M
Relative Volume:
0.45
Market Cap:
$8.50B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-21.20
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-20.59%
1M Performance:
+19.62%
6M Performance:
+222.57%
1Y Performance:
+176.33%
1-Day Range:
$8.08
$8.7899
1-Week Range:
$8.08
$10.58
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.2686 | 8.91B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.93 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.38 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.37 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.44 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.69 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Benzinga
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable
ImmunityBio Resubmits Ankitva Application To FDA With Additional Data — IBRX Stock Declines Pre-Market - Stocktwits
ImmunityBio resubmits bladder cancer application to FDA - Investing.com
FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan
ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal
How dovish Fed policy supports ImmunityBio Inc. (26CA) stock2026 Technicals & Weekly Market Pulse Alerts - Naître et grandir
How ImmunityBio Inc. stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Entry High Yield Tips - Naître et grandir
ImmunityBio (NASDAQ:IBRX) Trading Down 3.2%Time to Sell? - MarketBeat
H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating - Bitget
ImmunityBio ANKTIVA Milestones Reshape Growth Outlook And Risk Profile - Sahm
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - Nasdaq
ImmunityBio Bladder Cancer Milestone Raises Questions On Global ANKTIVA Rollout - Yahoo Finance
ImmunityBio (IBRX) Is Down 5.8% After ANKTIVA Rollout Fuels Revenue Jump And Narrower Losses - Yahoo Finance
Piper Sandler Maintains Overweight on ImmunityBio (IBRX) March 2026 - Meyka
ImmunityBio Shares Retreat Despite Strong Commercial Momentum - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 10.2%What's Next? - MarketBeat
ImmunityBio Director’s Share Sale Spurs Investigations: Stock Faces Downturn - timothysykes.com
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth - The Chronicle-Journal
ImmunityBio (NASDAQ:IBRX) Shares Gap DownTime to Sell? - MarketBeat
Major Director Share Sale Hits ImmunityBio Stock - StocksToTrade
ImmunityBio (IBRX) Shares Drop Nearly 10% as Investors Digest Recent Earnings - International Business Times Australia
ImmunityBio Faces Increased Investor Skepticism Amid Recent Developments - timothysykes.com
ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target - TipRanks
Piper Sandler raises Immunitybio stock price target on revenue growth - Investing.com
IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside - Stocktwits
ImmunityBio, Inc. (IBRX) Price Target Raised After Strong ANKTIVA Launch - Finviz
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions - Stocktwits
ImmunityBio (IBRX) Is Down 13.4% After ANKTIVA Data And New EMEA DealsWhat's Changed - simplywall.st
ImmunityBio Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: ImmunityBio’s Q4 2025 EPS beats forecast, stock surges - Investing.com Nigeria
IBRX: 700% revenue growth and global expansion highlight a transformational year for ANKTIVA - TradingView
ImmunityBio (NASDAQ:IBRX) Shares Down 4.2%Should You Sell? - MarketBeat
ImmunityBio, Inc. (IBRX) Stock Analysis: A Biotech Powerhouse With 29% Upside Potential - DirectorsTalk Interviews
ImmunityBio (IBRX) stock wobbles in premarket ahead of update call — what traders are watching - TechStock²
ImmunityBio, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook - Stocktwits
Citigroup Inc. Decreases Stake in ImmunityBio, Inc. $IBRX - MarketBeat
A Look At ImmunityBio (IBRX) Valuation After ANKTIVA Trial Progress And New Regulatory Milestones - simplywall.st
ImmunityBio (NASDAQ:IBRX) Trading 6.7% Higher Following Better-Than-Expected Earnings - MarketBeat
ImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX) - MarketBeat
ImmunityBio Surges After European Approval Boosts ANKTIVA’s Global Reach - StocksToTrade
ImmunityBio Advances Chemotherapy Free Immunotherapies And Faces Key Investor Tests - Sahm
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 - marketscreener.com
ImmunityBio, Inc. (IBRX) Competitors - Meyka
IBRX (ImmunityBio) pre-market: Q4 2025 results Mar 3, 2026 could move stock - Meyka
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):